Skip to main content
. 2017 Dec 23;9(3):4061–4073. doi: 10.18632/oncotarget.23664

Figure 2. Survival outcomes separated by obesity and metformin use.

Figure 2

(A) Kaplan Meier curve for overall survival for patients in BMI group: A ≤ 18.5 (black); B 18.6 – 34.9 (red); and C ≥ 35 (green), p = 0.02. C. (B) Kaplan Meier curve for freedom from failure for patients in BMI group: A ≤ 18.5 (black); B 18.6 – 34.9 (red); and C ≥ 35 (green), p = 0.01. (C) Kaplan Meier curve for overall survival for patients from BMI group C with (red) and without (black) metformin use (p=0.71) (D) Kaplan Meier curve for freedom from failure for patients from BMI group C with (red) and without (black) metformin use (p=0.83). (E) Kaplan Meier curve for overall survival for patients from BMI group C with (red) and without (black) insulin use (p=0.33). (F) Kaplan Meier curve for freedom from failure for patients from BMI group C with (red) and without (black) insulin use (p=0.43). (G) Kaplan Meier curve for overall survival for patients from BMI group C with (red) and without (black) a diagnosis of diabetes (p=0.62). (H) Kaplan Meier curve for freedom from failure for patients from BMI group C with (red) and without (black) a diagnosis of diabetes (p=0.59).